- Previous Close
0.0003 - Open
0.0003 - Bid 0.0052 x --
- Ask 0.0110 x --
- Day's Range
0.0003 - 0.0003 - 52 Week Range
0.0002 - 0.0190 - Volume
240 - Avg. Volume
2,567 - Market Cap (intraday)
18,572 - Beta (5Y Monthly) 1.89
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.
www.novaccessglobal.comRecent News: XSNX
View MorePerformance Overview: XSNX
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XSNX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XSNX
View MoreValuation Measures
Market Cap
18.57k
Enterprise Value
2.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-337.19%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-1.89M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
794
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
86.05k